Shopping Cart 0
Cart Subtotal
USD 0

Aurigene Discovery Technologies Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aurigene Discovery Technologies Ltd (Aurigene), a subsidiary of Dr. Reddy's Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene's pipeline portfolio consists of products for immunoncology PD-L1 and Vista, TIM-3 and PD1, CD47; precision oncology products IRAK4, NAMPT, KRAS, CDK7; Epigenetics products BET Bromodomain, PRMT5, CBP and P300; and inflammatory product ROR Inverse Agonist. It operates through collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.

Aurigene Discovery Technologies Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Aurigene Discovery Enters into Agreement with Curis 10

Licensing Agreements 12

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 12

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 13

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 15

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 16

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 17

Aurigene Discovery Technologies Ltd-Key Competitors 18

Aurigene Discovery Technologies Ltd-Key Employees 19

Aurigene Discovery Technologies Ltd-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Product News 21

03/31/2017: Aurigene to Present Data on CD47-SIRPI interaction program at the AACR 2017 21

03/31/2017: Aurigene to Present Data on MALT-1 Signalling Program at the AACR 2017 22

Clinical Trials 23

Jan 17, 2018: Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma 23

Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit 24

Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit 25

Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017 26

Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress 27

May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting 28

Mar 30, 2017: Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30


List Of Figure

List of Figures

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aurigene Discovery Technologies Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aurigene Discovery Enters into Agreement with Curis 10

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 12

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 13

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 15

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 16

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 17

Aurigene Discovery Technologies Ltd, Key Competitors 18

Aurigene Discovery Technologies Ltd, Key Employees 19

Aurigene Discovery Technologies Ltd, Other Locations 20

Aurigene Discovery Technologies Ltd, Subsidiaries 20

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aurigene Discovery Technologies Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aurigene Discovery Technologies Ltd (Aurigene), a subsidiary of Dr. Reddy's Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene's pipeline portfolio consists of products for immunoncology PD-L1 and Vista, TIM-3 and PD1, CD47; precision oncology products IRAK4, NAMPT, KRAS, CDK7; Epigenetics products BET Bromodomain, PRMT5, CBP and P300; and inflammatory product ROR Inverse Agonist. It operates through collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.

Aurigene Discovery Technologies Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Aurigene Discovery Enters into Agreement with Curis 10

Licensing Agreements 12

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 12

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 13

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 15

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 16

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 17

Aurigene Discovery Technologies Ltd-Key Competitors 18

Aurigene Discovery Technologies Ltd-Key Employees 19

Aurigene Discovery Technologies Ltd-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Product News 21

03/31/2017: Aurigene to Present Data on CD47-SIRPI interaction program at the AACR 2017 21

03/31/2017: Aurigene to Present Data on MALT-1 Signalling Program at the AACR 2017 22

Clinical Trials 23

Jan 17, 2018: Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma 23

Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit 24

Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit 25

Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017 26

Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress 27

May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting 28

Mar 30, 2017: Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30


List Of Figure

List of Figures

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aurigene Discovery Technologies Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aurigene Discovery Enters into Agreement with Curis 10

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 12

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 13

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 15

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 16

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 17

Aurigene Discovery Technologies Ltd, Key Competitors 18

Aurigene Discovery Technologies Ltd, Key Employees 19

Aurigene Discovery Technologies Ltd, Other Locations 20

Aurigene Discovery Technologies Ltd, Subsidiaries 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aurigene Discovery Technologies Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.